Report cover image

Global Blood Plasma Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 197 Pages
SKU # APRC20556572

Description

Summary

According to APO Research, the global Blood Plasma market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Blood Plasma is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Blood Plasma is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Blood Plasma market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Blood Plasma is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Blood Plasma market include Shanghai Raas, Baxter International, TCS Biosciences, Sanquin, Octapharma, Grifols, CSL, Cerus Corp and ADMA Biologics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Blood Plasma, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Blood Plasma, also provides the sales of main regions and countries. Of the upcoming market potential for Blood Plasma, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Blood Plasma sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Blood Plasma market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Blood Plasma sales, projected growth trends, production technology, application and end-user industry.

Blood Plasma Segment by Company

Shanghai Raas
Baxter International
TCS Biosciences
Sanquin
Octapharma
Grifols
CSL
Cerus Corp
ADMA Biologics
Blood Plasma Segment by Type

Protease Inhibitors
Coagulation Factor Concentrates
Immunoglobulin
Albumin
Others
Blood Plasma Segment by Application

Hospitals and Clinics
Research Laboratories
Academic Institutions
Blood Plasma Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Blood Plasma status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Blood Plasma market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Blood Plasma significant trends, drivers, influence factors in global and regions.
6. To analyze Blood Plasma competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Blood Plasma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Blood Plasma and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Blood Plasma.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Blood Plasma market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Blood Plasma industry.
Chapter 3: Detailed analysis of Blood Plasma manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Blood Plasma in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Blood Plasma in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Blood Plasma Sales Value (2020-2031)
1.2.2 Global Blood Plasma Sales Volume (2020-2031)
1.2.3 Global Blood Plasma Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Blood Plasma Market Dynamics
2.1 Blood Plasma Industry Trends
2.2 Blood Plasma Industry Drivers
2.3 Blood Plasma Industry Opportunities and Challenges
2.4 Blood Plasma Industry Restraints
3 Blood Plasma Market by Company
3.1 Global Blood Plasma Company Revenue Ranking in 2024
3.2 Global Blood Plasma Revenue by Company (2020-2025)
3.3 Global Blood Plasma Sales Volume by Company (2020-2025)
3.4 Global Blood Plasma Average Price by Company (2020-2025)
3.5 Global Blood Plasma Company Ranking (2023-2025)
3.6 Global Blood Plasma Company Manufacturing Base and Headquarters
3.7 Global Blood Plasma Company Product Type and Application
3.8 Global Blood Plasma Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Blood Plasma Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Blood Plasma Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Blood Plasma Market by Type
4.1 Blood Plasma Type Introduction
4.1.1 Protease Inhibitors
4.1.2 Coagulation Factor Concentrates
4.1.3 Immunoglobulin
4.1.4 Albumin
4.1.5 Others
4.2 Global Blood Plasma Sales Volume by Type
4.2.1 Global Blood Plasma Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Blood Plasma Sales Volume by Type (2020-2031)
4.2.3 Global Blood Plasma Sales Volume Share by Type (2020-2031)
4.3 Global Blood Plasma Sales Value by Type
4.3.1 Global Blood Plasma Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Blood Plasma Sales Value by Type (2020-2031)
4.3.3 Global Blood Plasma Sales Value Share by Type (2020-2031)
5 Blood Plasma Market by Application
5.1 Blood Plasma Application Introduction
5.1.1 Hospitals and Clinics
5.1.2 Research Laboratories
5.1.3 Academic Institutions
5.2 Global Blood Plasma Sales Volume by Application
5.2.1 Global Blood Plasma Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Blood Plasma Sales Volume by Application (2020-2031)
5.2.3 Global Blood Plasma Sales Volume Share by Application (2020-2031)
5.3 Global Blood Plasma Sales Value by Application
5.3.1 Global Blood Plasma Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Blood Plasma Sales Value by Application (2020-2031)
5.3.3 Global Blood Plasma Sales Value Share by Application (2020-2031)
6 Blood Plasma Regional Sales and Value Analysis
6.1 Global Blood Plasma Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Blood Plasma Sales by Region (2020-2031)
6.2.1 Global Blood Plasma Sales by Region: 2020-2025
6.2.2 Global Blood Plasma Sales by Region (2026-2031)
6.3 Global Blood Plasma Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Blood Plasma Sales Value by Region (2020-2031)
6.4.1 Global Blood Plasma Sales Value by Region: 2020-2025
6.4.2 Global Blood Plasma Sales Value by Region (2026-2031)
6.5 Global Blood Plasma Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Blood Plasma Sales Value (2020-2031)
6.6.2 North America Blood Plasma Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Blood Plasma Sales Value (2020-2031)
6.7.2 Europe Blood Plasma Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Blood Plasma Sales Value (2020-2031)
6.8.2 Asia-Pacific Blood Plasma Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Blood Plasma Sales Value (2020-2031)
6.9.2 South America Blood Plasma Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Blood Plasma Sales Value (2020-2031)
6.10.2 Middle East & Africa Blood Plasma Sales Value Share by Country, 2024 VS 2031
7 Blood Plasma Country-level Sales and Value Analysis
7.1 Global Blood Plasma Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Blood Plasma Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Blood Plasma Sales by Country (2020-2031)
7.3.1 Global Blood Plasma Sales by Country (2020-2025)
7.3.2 Global Blood Plasma Sales by Country (2026-2031)
7.4 Global Blood Plasma Sales Value by Country (2020-2031)
7.4.1 Global Blood Plasma Sales Value by Country (2020-2025)
7.4.2 Global Blood Plasma Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Blood Plasma Sales Value Growth Rate (2020-2031)
7.5.2 USA Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Blood Plasma Sales Value Growth Rate (2020-2031)
7.6.2 Canada Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Blood Plasma Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Blood Plasma Sales Value Growth Rate (2020-2031)
7.8.2 Germany Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Blood Plasma Sales Value Growth Rate (2020-2031)
7.9.2 France Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.9.3 France Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Blood Plasma Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Blood Plasma Sales Value Growth Rate (2020-2031)
7.11.2 Italy Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Blood Plasma Sales Value Growth Rate (2020-2031)
7.12.2 Spain Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Blood Plasma Sales Value Growth Rate (2020-2031)
7.13.2 Russia Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Blood Plasma Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Blood Plasma Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Blood Plasma Sales Value Growth Rate (2020-2031)
7.16.2 China Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.16.3 China Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Blood Plasma Sales Value Growth Rate (2020-2031)
7.17.2 Japan Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Blood Plasma Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Blood Plasma Sales Value Growth Rate (2020-2031)
7.19.2 India Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.19.3 India Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Blood Plasma Sales Value Growth Rate (2020-2031)
7.20.2 Australia Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Blood Plasma Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Blood Plasma Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Blood Plasma Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Blood Plasma Sales Value Growth Rate (2020-2031)
7.24.2 Chile Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Blood Plasma Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Blood Plasma Sales Value Growth Rate (2020-2031)
7.26.2 Peru Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Blood Plasma Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Blood Plasma Sales Value Growth Rate (2020-2031)
7.28.2 Israel Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Blood Plasma Sales Value Growth Rate (2020-2031)
7.29.2 UAE Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Blood Plasma Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Blood Plasma Sales Value Growth Rate (2020-2031)
7.31.2 Iran Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Blood Plasma Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Blood Plasma Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Blood Plasma Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Blood Plasma Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Shanghai Raas
8.1.1 Shanghai Raas Comapny Information
8.1.2 Shanghai Raas Business Overview
8.1.3 Shanghai Raas Blood Plasma Sales, Value and Gross Margin (2020-2025)
8.1.4 Shanghai Raas Blood Plasma Product Portfolio
8.1.5 Shanghai Raas Recent Developments
8.2 Baxter International
8.2.1 Baxter International Comapny Information
8.2.2 Baxter International Business Overview
8.2.3 Baxter International Blood Plasma Sales, Value and Gross Margin (2020-2025)
8.2.4 Baxter International Blood Plasma Product Portfolio
8.2.5 Baxter International Recent Developments
8.3 TCS Biosciences
8.3.1 TCS Biosciences Comapny Information
8.3.2 TCS Biosciences Business Overview
8.3.3 TCS Biosciences Blood Plasma Sales, Value and Gross Margin (2020-2025)
8.3.4 TCS Biosciences Blood Plasma Product Portfolio
8.3.5 TCS Biosciences Recent Developments
8.4 Sanquin
8.4.1 Sanquin Comapny Information
8.4.2 Sanquin Business Overview
8.4.3 Sanquin Blood Plasma Sales, Value and Gross Margin (2020-2025)
8.4.4 Sanquin Blood Plasma Product Portfolio
8.4.5 Sanquin Recent Developments
8.5 Octapharma
8.5.1 Octapharma Comapny Information
8.5.2 Octapharma Business Overview
8.5.3 Octapharma Blood Plasma Sales, Value and Gross Margin (2020-2025)
8.5.4 Octapharma Blood Plasma Product Portfolio
8.5.5 Octapharma Recent Developments
8.6 Grifols
8.6.1 Grifols Comapny Information
8.6.2 Grifols Business Overview
8.6.3 Grifols Blood Plasma Sales, Value and Gross Margin (2020-2025)
8.6.4 Grifols Blood Plasma Product Portfolio
8.6.5 Grifols Recent Developments
8.7 CSL
8.7.1 CSL Comapny Information
8.7.2 CSL Business Overview
8.7.3 CSL Blood Plasma Sales, Value and Gross Margin (2020-2025)
8.7.4 CSL Blood Plasma Product Portfolio
8.7.5 CSL Recent Developments
8.8 Cerus Corp
8.8.1 Cerus Corp Comapny Information
8.8.2 Cerus Corp Business Overview
8.8.3 Cerus Corp Blood Plasma Sales, Value and Gross Margin (2020-2025)
8.8.4 Cerus Corp Blood Plasma Product Portfolio
8.8.5 Cerus Corp Recent Developments
8.9 ADMA Biologics
8.9.1 ADMA Biologics Comapny Information
8.9.2 ADMA Biologics Business Overview
8.9.3 ADMA Biologics Blood Plasma Sales, Value and Gross Margin (2020-2025)
8.9.4 ADMA Biologics Blood Plasma Product Portfolio
8.9.5 ADMA Biologics Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Blood Plasma Value Chain Analysis
9.1.1 Blood Plasma Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Blood Plasma Sales Mode & Process
9.2 Blood Plasma Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Blood Plasma Distributors
9.2.3 Blood Plasma Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.